In about 3–5% of NSCLC individuals, the oncogenic anaplastic lymphoma kinase (ALK) gene rearrangement occurs (5–7), which represents a molecularly and clinically diverse subtype of NSCLC sensitive to ALK tyrosine kinase inhibitors (5, 8, 9). The gene discussed is ALK; the disease is non-small cell lung carcinoma.